secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-05-21T21:04:12+00:00
Accession:  0001674930-26-000025
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent reports FID-007 + cetuximab Phase 2 HNSCC data: 60% ORR, 7.2 mo mPFS
----------------------------------------------------------------------------

- Interim Phase 2 data: ORR 60% (58% Arm A, 61% Arm B); mPFS 7.2 months across 42 evaluable patients.
- Median DoR 7.4 months; 56% of responders still responding at Dec 20, 2025 cut-off; OS immature.
- Favorable safety: mostly Grade 1-2 TRAEs; Grade 3-4 neutropenia, anemia, leukopenia; one Grade 5 pneumonia (Arm B).
- Abstract #6020 presented at ASCO 2026 Rapid Oral Session on June 1, 2026 in Chicago.
- Company notes historical standard-of-care offers ORR 5.8%-19.1% and PFS 2.3-3.7 months in R/M HNSCC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000025/0001674930-26-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000025/flgt-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001674930-26-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer